See more : PharmaCyte Biotech, Inc. (PMCB) Income Statement Analysis – Financial Results
Complete financial analysis of Shandong Sanyuan Biotechnology Co.,Ltd. (301206.SZ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Shandong Sanyuan Biotechnology Co.,Ltd., a leading company in the Food Confectioners industry within the Consumer Defensive sector.
- Enterprise 4.0 Technology Acquisition Corp. (ENTF) Income Statement Analysis – Financial Results
- Arcadis NV (ARCVF) Income Statement Analysis – Financial Results
- Compute Health Acquisition Corp (CPUH-WT) Income Statement Analysis – Financial Results
- BKW AG (BKW.SW) Income Statement Analysis – Financial Results
- WisdomTree Crypto Altcoins (GB00BMTP1519.AS) Income Statement Analysis – Financial Results
Shandong Sanyuan Biotechnology Co.,Ltd. (301206.SZ)
About Shandong Sanyuan Biotechnology Co.,Ltd.
Shandong Sanyuan Biotechnology Co., Ltd. engages in the research and development, production, and sales of erythritol and compound sugar products in China. Its products are used in table sugar, flavored sugar, beverages; candy, chocolate food; baked food; health food; pharmaceutical products; cosmetic products; chemical products; and other applications. The company exports its products to Europe, the United States, East Asia, Southeast Asia, Australia, New Zealand, and Africa. Shandong Sanyuan Biotechnology Co., Ltd. was founded in 2007 and is headquartered in Binzhou, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 496.81M | 674.91M | 1.68B | 783.18M | 476.76M | 292.20M | 120.96M | 88.90M | 40.08M | 20.06M | 19.20M |
| Cost of Revenue | 485.47M | 580.05M | 971.83M | 452.14M | 258.53M | 184.53M | 82.92M | 63.35M | 32.82M | 15.66M | 15.04M |
| Gross Profit | 11.34M | 94.86M | 703.49M | 331.04M | 218.23M | 107.68M | 38.03M | 25.55M | 7.26M | 4.40M | 4.16M |
| Gross Profit Ratio | 2.28% | 14.06% | 41.99% | 42.27% | 45.77% | 36.85% | 31.44% | 28.74% | 18.12% | 21.93% | 21.67% |
| Research & Development | 50.66M | 34.08M | 59.00M | 30.34M | 19.45M | 14.99M | 12.04M | 0.00 | 0.00 | 591.15K | 670.87K |
| General & Administrative | 2.59M | 4.73M | 4.24M | -17.11M | -9.06M | -7.64M | -5.75M | 6.71M | 3.96M | 321.23K | 363.96K |
| Selling & Marketing | 3.09M | 5.19M | 5.47M | 3.89M | 16.78M | 10.65M | 5.40M | 2.82M | 1.11M | 717.47K | 1.01M |
| SG&A | 5.69M | 9.92M | 9.71M | -13.23M | 7.72M | 3.01M | -347.77K | 9.53M | 5.07M | 1.04M | 1.37M |
| Other Expenses | -118.17M | -2.10M | 125.41K | 26.02M | -7.48M | -7.01M | 300.36K | 0.00 | 0.00 | 283.50K | 283.84K |
| Operating Expenses | -47.35M | 46.44M | 78.33M | 48.41M | 45.27M | 30.70M | 15.98M | 10.29M | 5.28M | 3.57M | 3.54M |
| Cost & Expenses | 438.12M | 626.49M | 1.05B | 500.55M | 303.80M | 215.23M | 98.90M | 73.64M | 38.09M | 19.23M | 18.59M |
| Interest Income | 5.35M | 13.86M | 3.50M | 8.27M | 3.45M | 2.02M | 1.03M | 120.78K | 50.44K | 5.49K | 2.97K |
| Interest Expense | 193.03K | 272.41K | 943.06 | 388.50K | 242.00K | 144.17K | 93.11K | 0.00 | 0.00 | 667.74K | 323.07K |
| Depreciation & Amortization | 59.61M | 38.75M | 25.65M | 16.89M | 10.53M | 7.28M | 3.23M | 579.57K | 1.35M | 1.30M | 1.13M |
| EBITDA | 267.72K | 69.33M | 641.90M | 287.42M | 182.00M | 84.76M | 24.99M | 15.47M | 3.44M | 2.48M | 1.80M |
| EBITDA Ratio | 0.05% | 32.47% | 38.57% | 38.28% | 41.72% | 28.87% | 20.83% | 17.40% | 8.58% | 12.23% | 9.65% |
| Operating Income | 61.38M | 186.05M | 619.77M | 273.13M | 159.16M | 78.60M | 21.84M | 14.89M | 2.09M | 232.56K | 70.97K |
| Operating Income Ratio | 12.35% | 27.57% | 36.99% | 34.87% | 33.38% | 26.90% | 18.05% | 16.74% | 5.22% | 1.16% | 0.37% |
| Total Other Income/Expenses | 332.70K | -2.10M | 125.41K | -2.98M | -1.02M | -101.20K | 105.24K | 470.94K | 84.06K | 283.50K | 283.84K |
| Income Before Tax | 61.71M | 183.96M | 619.90M | 270.14M | 158.14M | 78.49M | 21.94M | 15.39M | 2.04M | 516.06K | 354.81K |
| Income Before Tax Ratio | 12.42% | 27.26% | 37.00% | 34.49% | 33.17% | 26.86% | 18.14% | 17.31% | 5.08% | 2.57% | 1.85% |
| Income Tax Expense | 2.84M | 20.27M | 84.48M | 37.57M | 21.83M | 10.41M | 3.24M | 1.44M | 0.00 | 921.59K | 656.26K |
| Net Income | 58.87M | 163.69M | 535.42M | 232.57M | 136.31M | 68.09M | 18.70M | 13.94M | 2.04M | 516.06K | 354.81K |
| Net Income Ratio | 11.85% | 24.25% | 31.96% | 29.70% | 28.59% | 23.30% | 15.46% | 15.68% | 5.08% | 2.57% | 1.85% |
| EPS | 0.29 | 0.81 | 2.65 | 1.15 | 0.67 | 0.46 | 0.13 | 0.16 | 0.03 | 0.02 | 0.01 |
| EPS Diluted | 0.29 | 0.81 | 2.65 | 1.15 | 0.67 | 0.46 | 0.13 | 0.16 | 0.03 | 0.02 | 0.01 |
| Weighted Avg Shares Out | 203.02M | 202.33M | 202.33M | 202.33M | 202.33M | 146.99M | 140.28M | 87.14M | 61.17M | 30.00M | 30.07M |
| Weighted Avg Shares Out (Dil) | 203.02M | 202.33M | 202.33M | 202.33M | 202.33M | 146.99M | 140.28M | 87.14M | 61.17M | 30.00M | 30.07M |
Source: https://incomestatements.info
Category: Stock Reports